These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23259327)

  • 1. Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid.
    Manivannan P; Siddaraju N; Jatiya L; Verma SK
    Indian J Biochem Biophys; 2012 Oct; 49(5):392-4. PubMed ID: 23259327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms.
    Matesa-Anić D; Moslavac S; Matesa N; Cupić H; Kusić Z
    Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM; Ibrahim TR
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
    Mataraci EA; Ozgüven BY; Kabukçuoglu F
    Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
    de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
    Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
    Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
    Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
    Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
    Aron M; Kapila K; Verma K
    Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
    Torregrossa L; Faviana P; Camacci T; Materazzi G; Berti P; Minuto M; Elisei R; Vitti P; Miccoli P; Basolo F
    Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
    Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
    Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
    Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
    Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
    Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
    Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
    Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
    Cui W; Sang W; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.
    Scognamiglio T; Hyjek E; Kao J; Chen YT
    Am J Clin Pathol; 2006 Nov; 126(5):700-8. PubMed ID: 17050067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
    Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
    Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Low galectin-3 capacity to discriminate thyroid lesions].
    De-León-Mazariegos R; Canedo-Patzi M; Pérez-Enríquez B; Candanedo-Gonzalez F; Saqui-Salces M; Gamboa-Domínguez A; Rull-Rodrigo JA
    Rev Invest Clin; 2004; 56(5):623-8. PubMed ID: 15776867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
    Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
    Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.